Drug Profile
Research programme: olfactory epithelium stem cell therapy - RhinoCyte
Latest Information Update: 11 Sep 2023
Price :
$50
*
At a glance
- Originator RhinoCyte
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Neurodegenerative disorders; Spinal cord injuries
Most Recent Events
- 11 Sep 2023 Discontinued - Preclinical for Neurodegenerative disorders in USA (Intralesional)
- 11 Sep 2023 Discontinued - Preclinical for Spinal cord injuries in USA (Intralesional)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in USA (Intralesional, Injection)